Ultrasound Guided Stellate Ganglion Block in Management of Postmastectomy Pain Syndrome

Ultrasound Guided Stellate Ganglion Block in Management of Postmastectomy Pain Syndrome: Anterior versus Lateral versus Combined Approach

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202605858727937

Enrollment

Registered

2026-05-19

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Surgery Anaesthesia

Interventions

Anterior Stellate Ganglion Block

Lateral Stellate Ganglion Block

Antrolateral Stellate Ganglion Block

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: • Adult female (20-70 years), • ASA I, II. • Complaining of post mastectomy chronic neuropathic pain (moderate to severe) lasting more than 6 months after modified radical mastectomy.

Exclusion criteria

Exclusion criteria: • Patient's refusal. • Infection or deformity at the area of injection. • Coagulopathies. • Distant metastasis. • Cardiac, diabetic, hepatic or renal patients. • Allergy to study drugs. • History of neuromuscular disease, stroke, arrhythmia. • BMI >30 kg/m2.

Design outcomes

Primary

Measure	Time frame
Primary outcome was based on mean change in pain score pre -and post stellate ganglion block at the 3rd month post-injection. The intensity of pain will be assessed by the Numeric Pain Intensity Scale (NPIS) on the scale from 0 to 10, where 0 indicates no pain and 10 indicates the worst pain imaginable.	—

Secondary

Measure	Time frame
.Brief pain inventory (BPI-SF) at the following intervals: •Seven items measuring interference with daily functioning (general activity, walking, work, mood, relations with others, sleep, and enjoyment of life) •Functional improvement. •Range of motion of the arm (flexion, extension, abduction, and internal and external rotation) will be assessed before and after injection. •Patient satisfaction at 3 and 6 months. •Hemodynamics and ipsilateral temperature. •The time of complete resolution of pain will be recorded in each patient. •The analgesic concomitant medications (Narcotic and pregabalin) consumption were assessed prior to the block and at 1, 4, 12, and 24 weeks thereafter. •Horner’s syndrome and immediate complications like hoarseness of voice, hematoma, weakness in the limb, respiratory insufficiency or signs of LA toxicity.	—

Measure

Time frame

.Brief pain inventory (BPI-SF) at the following intervals: •Seven items measuring interference with daily functioning (general activity, walking, work, mood, relations with others, sleep, and enjoyment of life) •Functional improvement. •Range of motion of the arm (flexion, extension, abduction, and internal and external rotation) will be assessed before and after injection. •Patient satisfaction at 3 and 6 months. •Hemodynamics and ipsilateral temperature. •The time of complete resolution of pain will be recorded in each patient. •The analgesic concomitant medications (Narcotic and pregabalin) consumption were assessed prior to the block and at 1, 4, 12, and 24 weeks thereafter. •Horner’s syndrome and immediate complications like hoarseness of voice, hematoma, weakness in the limb, respiratory insufficiency or signs of LA toxicity.

—

Countries

Egypt

Contacts

Public ContactGhada Fouad Weefky

Professor of Anesthesia and Surgical ICU. Faculty of Medicine.

dr_tarekhabeeb@yahoo.com+201005663554

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026